Izumerogant

N/A

Report date: 2025/05/13 16:53:25
NME

Base Information

Drug NameIzumerogant
Drug Alias NameIMU-935
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNuclear receptor ROR-gamma inverse agonistsInterleukin-17 inhibitorsDihydroorotate dehydrogenase inhibitors
TargetsNuclear receptor ROR-gammaInterleukin-17Dihydroorotate dehydrogenase
Therapy Area/IndicationsProstatic Neoplasms, Castration-Resistant
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesImmunic Ag
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesImmunic Ag
Active IndicationsN/A
Inactive IndicationsProstatic Neoplasms, Castration-Resistant

Other Information

ATC CodeN/A
Related LinksN/A